Gossamer Bio, Inc. 8K

Gossamer Bio is implementing a 1-for-80 reverse stock split and major authorized share reduction to regain compliance with Nasdaq’s minimum bid price requirement, effective September 10, 2026.

Gossamer Bio, Inc. announced that its board of directors has approved a 1-for-80 reverse stock split of its common stock, along with a proportionate reduction of authorized common shares from 4,000,000,000 to 50,000,000 and total authorized capital stock from 4,070,000,000 to 120,000,000, effective at 11:59 p.m. Eastern Time on September 10, 2026, with split-adjusted trading to begin on the Nasdaq Global Select Market on September 11, 2026 under the existing ticker GOSS and a new CUSIP. The reverse split, previously authorized by stockholders at a July 14, 2026 special meeting, is intended to help the company regain compliance with Nasdaq’s minimum bid price requirement and will include proportional adjustments to the conversion and exercise terms of outstanding convertible notes, warrants, prefunded warrants, and equity awards, while avoiding fractional shares by rounding holdings up to the nearest whole share; stockholders’ percentage ownership and voting power will remain essentially unchanged aside from minor effects from fractional share treatment.

Filing Facts

CIK

1728117

Ticker

-

Form

8K

Source Type

sec

Accession

0001728117-26-000091

Alert Tier

7